PTH-related protein-(107-139) ] has been reported previously to be a potent inhibitor of osteoclast activity. However, this finding has not been reproduced in other in vitro models. We have now examined the effects of this peptide in an in vivo model, employing intact adult mice. Four groups of eight male mice were given injections of either vehicle or one of three doses of PTHrP-(107-139) (4 ϫ 10 Ϫ13 , 4 ϫ 10
, or 4 ϫ 10 Ϫ9 mol) over the periosteum of the right hemicalvaria for 5 consecutive days. The animals were killed 1 week after the last injection.
There were significant decreases in bone resorption indexes after all doses of PTHrP-(107-139), with a 70% decrease in osteoclast number (P Ͻ 0.001), a 70% decrease in osteoclast perimeter (P ϭ 0.004), and a 50% decrease in eroded perimeter (P ϭ 0.001). In addition, some indexes of bone formation were significantly decreased, with 40% decreases in both osteoblast number (P ϭ 0.05) and osteoblast perimeter (P ϭ 0.02), but no significant change in osteoid area. There was a dose-related upward trend in mineralized bone area, reaching 12% at the highest dose, but this was not statistically significant. It is concluded that PTHrP-(107-139) is a potent inhibitor of bone resorption in vivo. As this model is very dissimilar to that of isolated osteoclasts, in which this peptide is also active, the present findings suggest that osteoclast inhibition is an authentic action of the Cterminus of PTHrP, which may, therefore, play a role in the regulation of bone turnover in vivo. (Endocrinology 138: 1299 -1304, 1997) P TH-RELATED protein (PTHrP) was identified in 1987 as the circulating factor producing humoral hypercalcemia of malignancy (1) (2) (3) . It is produced in a number of types of cancer cells, and its amino-terminal binds to the same receptor as PTH, thereby stimulating bone resorption. The homology between PTH and PTHrP is only found at their amino-terminals, where 8 of the first 13 amino acids are identical in the 2 peptides. Otherwise the 2 peptides are structurally and functionally distinct.
Full-length recombinant PTHrP-(1-141) has been shown to inhibit bone resorption by isolated osteoclasts (4) , and further investigation of this phenomenon showed that the antiosteoclastic effects of PTHrP reside in the C-terminal region of the peptide beyond residue 106. This activity has been referred to as osteostatin (5) . Both PTHrP-(107-139) and PTHrP-(107-111) inhibit resorption by isolated osteoclasts with half-maximal concentrations of 10 Ϫ15 m (5). An antiresorptive effect of PTHrP-(107-139) has been demonstrated in cultured fetal rat long bones (4), but Sone et al. (6) and our own group (Cornish, J., et al., unpublished data) have failed to demonstrate any effect of this peptide on bone resorption in neonatal mouse calvarial organ culture. Recently, Murrills et al. (7) have reported no consistent effects of either PTHrP-(107-111) or PTHrP-(107-139) on resorption by isolated rat and chick osteoclasts, and Kaji et al. (8) have produced comparable negative findings in mouse osteoclasts. In addition, however, the latter showed stimulation of osteoclast-like cell formation by the carboxyl-terminal peptides of PTHrP.
Thus, there is considerable inconsistency in the available data regarding the effects of the carboxyl-terminus of PTHrP on bone resorption. Some of these inconsistencies may be attributable to the use of different models with different proportions of osteoclast precursors and mature osteoclasts. The present report seeks to determine how potentially conflicting effects on osteoclast maturation and on the activity of mature osteoclasts might be balanced in vivo in mature bone by injecting PTHrP-(107-139) over the calvariae of adult mice. The results of these studies demonstrate a substantial dose-related inhibition of bone resorption in the calvariae of treated mice, suggesting that this peptide may play a significant role in the regulation of osteoclast activity in vivo.
Materials and Methods

Experimental design
Four groups, each of eight sexually mature male ARC Swiss-Webster mice aged between 40 -50 days and weighing 25-35 g, were given injections (25 l) over the periosteum of the right hemicalvaria for 5 consecutive days. Previous studies with dye injections have shown that the injected material spreads over much of the injected hemicalvaria, but does not cross the midline. The animals were maintained on a low calcium diet (0.1%) from 5 days before the first injection. Three of the groups of mice were injected with PTHrP-(107-139) in doses of 4 ϫ 10 Ϫ13 , 4 ϫ 10 Ϫ11 , or 4 ϫ 10 Ϫ9 mol/injection, respectively. The highest of these doses was chosen based on our experience with other bone-active peptides (e.g. calcitonin) in this model, and the two lower doses derived from this to gauge the potency of this peptide over a wide dose range, relative to other peptides we have assessed in comparable experiments. Animals in the control group were injected with the vehicle (water) only. All animals were killed 1 week after the last injection. Each animal's weight was recorded at the beginning and end of the experiment. The study had the approval of the local institutional review board.
Gross morphology
The calvariae were dissected free of soft tissue, and any gross morphological changes were assessed by examination of the intact calvariae under a dissection microscope.
Histomorphometry
Bone tissue was fixed in 10% phosphate-buffered formalin, dehydrated in a graded series of ethanol solutions, and embedded undecalcified in methyl methacrylate resin. Sections (4 m thick) were cut on a JB-4 microtome (Sorvall Instruments, du Pont, DE) using a tungstencarbide knife and mounted on gelatin-coated slides and air-dried. The sections were stained with a Goldner tri-chrome stain and examined using an Olympus BX 50 microscope (Olympus Optical Co., Tokyo, Japan), which was attached to an Osteomeasure Image Analyzer (Osteometrics, Atlanta, GA). Histomorphometric analyses were made of three adjacent fields (using a ϫ20 objective) in each hemicalvaria. This results in measurements being made over Ͼ90% of the length of each hemicalvaria. The parameters assessed are as defined by the American Society for Bone and Mineral Research (9) and are expressed per mm calvarial length. Osteoblasts were defined as cells immediately adjacent to osteoid. Osteoclast numbers included only multinucleated cells. The various surface estimates were based on measurements of both periosteal and intramembranous surfaces; those eroded by osteoclasts (eroded perimeter), those immediately adjacent to osteoclasts (osteoclast perimeter), and those immediately adjacent to osteoblasts (osteoblast perimeter). The precision of these histomorphometric measurements in our laboratory (expressed as coefficients of variation of paired measurements) is as follows: mineralized bone area, 1.3%; osteoid area, 6.9%; osteoblast perimeter, 6.8%; osteoblast number, 1.7%; eroded perimeter, 6.7%; osteoclast perimeter, 7.9%; osteoclast number, less than 1.0%; calvarial length, 0.2%; and calvarial width, 1.7%. All measurements were made by one operator (J.C.), who was blinded to the treatment group of each bone.
Materials
Human PTHrP-(107-139) was generously provided by Dr. Bruce Kemp, St. Vincent's Institute of Medical Research (Victoria, Australia). It was stored at Ϫ70 C lyophilized as the hydrochloride salt and was redissolved in water.
Statistical analysis
Data have been presented in two formats. The primary end point for each histomorphometric index was the determination of whether it was different in the injected right hemicalvaria from the contralateral, uninjected bone of the same animal. The significance of these treatment effects were evaluated separately in each group using Student's t tests for paired data. These comparisons were made a priori, so adjustment of ␣ was not necessary. These data and the associated statistical significance are presented in the figures. Data are also presented as the mean of the histomorphometric indexes in the injected and uninjected hemicalvariae by treatment group. Data for the uninjected calvariae alone have been assessed by one-way ANOVA, and the complete dataset was analyzed using repeated measures ANOVA with the injected and uninjected sides as the repeated measures and group as the independent variable. Comparisons between different doses were made using Student's t tests for unpaired data, applying the Bonferroni inequality to preserve ␣ in the presence of multiple comparisons.
Results
There were no differences between the uninjected left hemicalvariae of the PTHrP-(107-139)-treated animals and those of the control animals (Table 1) . Also, vehicle treatment did not significantly affect any of the histomorphometric indexes assessed in the injected hemicalvariae (see lefthand bars in Figs. 2-9 ).
Significant morphological changes were seen in the right hemicalvariae compared to the uninjected left hemicalvariae in the PTHrP-(107-139)-treated animals, and the two halves of a typical bone are shown in Fig. 1 . The obvious difference associated with PTHrP-(107-139) treatment was a reduction in the number and size of the intramembranous spaces and the presence of fewer resorption pits, suggesting the peptide was inhibiting bone resorption.
Quantitative histomorphometry was consistent with this interpretation. There were significantly fewer osteoclasts in the hemicalvariae exposed to any dose of PTHrP-(107-139); the reduction in cell number reached 70% in animals treated with 4 ϫ 10 Ϫ9 moles ( Fig. 2 and Table 2 ). This effect was dose related in that the reduction in osteoclast number was significantly less in bones treated with the lowest dose of peptide than it was in those exposed to the two higher doses. Comparable decreases in the osteoclast perimeter and the eroded perimeter occurred, again significant at all doses studied, although there were not significant differences between doses for these parameters (Figs. 3 and 4 and Table 2 ).
Some indexes of bone formation were also significantly decreased by PTHrP-(107-139). The number of osteoblasts was diminished at the highest peptide dose, although a downward trend was also seen at the two lower doses (Fig.  5 and Table 2 ). Osteoblast perimeter (Fig. 6 and Table 2 ) was lower in the hemicalvariae treated with the middle and high doses of PTHrP-(107-139), but there was no significant change in osteoid area ( Fig. 7 and Table 2 ).
The area of mineralized bone tended to be higher after treatment with PTHrP-(107-139), but this was not statistically significant (P ϭ 0.13; Fig. 8 and Table 2 ). There was no difference in periosteal area between bones receiving active or vehicle treatment ( Fig. 9 and Table 2 ).
Weight gain was not different between the groups, and all of the animals remained in good health. There was no evidence of inflammatory cell infiltration in any of the histological sections. 
Discussion
The present data demonstrate a substantial inhibition of bone resorption in vivo by PTHrP-(107-139). These changes are consistent with the effects of this peptide on the function of isolated osteoclasts demonstrated previously by Fenton et al. (4, 5, 10, 11) . The experimental models used in those and the present studies, however, could not be more different. The present data are derived from in vivo studies in adult mice, in contrast to Fenton's work in cultures of isolated neonatal rat and embryonic chicken cells. Thus, the comparability of outcomes is striking and suggests that inhibition of bone resorption is a fundamental action of this peptide. That it might be relevant to the physiological regulation of bone turnover is suggested by the very low half-maximal concentrations found by Fenton and by the consistency of the inhibition over a 10,000-fold dose range in the present experiments. How the concentrations used in this study compare with those occurring in vivo is uncertain, because the initial high level will be rapidly reduced as a result of dilution by tissue fluid, diffusion of peptide away from the injection site, and enzymatic degradation. Thus, there may be no peptide present for much of each 24-h period, and the average peptide concentration may well be in the physiological range. There is a decreased number of resorption pits (RP) in the peptide-treated bone. Osteoid (Os) is seen on the intramembranous and periosteal (P) bone surfaces. The pale areas in the mineralized bone of (b) are sectioning artifacts that were seen with equal frequency in injected and uninjected hemicalvariae. Magnification, ϫ120. In addition to the reductions in indexes of bone resorption, there was significant suppression of some indexes of osteoblast function by PTHrP-(107-139). This is likely to result from coupling of formation to resorption, but it could also represent a direct effect on osteoblasts, as has recently been suggested by Martinez et al. in studies of the proliferation of isolated osteoblast-like cells (12) , or it could represent a nonspecific toxic effect of the injected peptide. The latter possibility is unlikely, however, because there was no evidence of a local inflammatory reaction, and we have now studied a variety of peptides in this model in doses comparable to the highest used here (and 10,000 times greater than the lowest used in the present study) and have never observed evidence of toxicity. On the contrary, we have found responses consistent with the known actions of these factors. Thus, PTH was found to markedly increase indexs of bone resorption (13), calcitonin was found to inhibit resorption (14), amylin was found to inhibit resorption and stimulate formation (14) , leukemia inhibitory factor was found to stimulate both formation and resorption (15) , insulin was found to stimulate formation alone (16) , and calcitonin gene-related peptide was found to have no effect (14) . The lack of any effect of calcitonin gene-related peptide argues against nonspecific effects of high dose peptides in this model. The changes in osteoblast indexes seen in the present results are, therefore, most likely be secondary to the changes in bone resorption and result from the coupling of these two processes that occurs in intact bone and is evident when other antiresorptive agents, such as bisphosphonates, are administered.
It is of interest to compare the activity of C-terminal PTHrP in this model with that of the established antiresorptive hormone, calcitonin. In a previous study (14) , we demonstrated that calcitonin in a dose of 4 ϫ 10 Ϫ9 mol produced effects on osteoclast perimeter comparable to those seen with PTHrP-(107-139) (4 ϫ 10 Ϫ11 mol) in the present study. There was also a trend toward fewer osteoclasts in calcitonin-treated bones, but this was not statistically significant, in contrast to PTHrP-(107-139), and this again suggests that calcitonin has an antiresorptive potency, which is significantly less than that of PTHrP-(107-139). This is consistent with the studies of Fenton et al. in long term cultures of osteoclasts, in which C-terminal PTHrP tended to produce greater inhibition of resorption than calcitonin (10) . The antiresorptive effects of PTHrP-(107-139) in the present study are comparable to those of amylin in the same model (14) , although amylin's action is distinct from that of PTHrP-(107-139) in that it increases indexes of osteoblast activity, in contrast to the diminution seen in the present study.
The present findings raise the question of why the published experience with osteostatin is so inconsistent. Murrills et al. (7) have discussed the discrepancies between their findings and those of Fenton et al. Although there were a number of differences in culture techniques between the two laboratories, it is not apparent which, if any, of these accounts for the different experimental outcomes. Before the work of Murrills, it had been suggested that the antiosteolytic effect of PTHrP-(107-139) was not seen in other studies, because these had used more complex models in which cells other than osteoclasts were present (i.e. bone organ culture). Both Murrills' and our own data refute this explanation, as Murrills did not find the effect in isolated osteoclast cultures and we did find it in intact animals. It is possible that differences in the origin of the peptides used or their handling might lead to different outcomes. Our own studies also tend to refute this suggestion because we could not demonstrate an effect of PTHrP-(107-139) in neonatal mouse calvarial cultures using the same batch of peptide that was clearly active in mice in vivo. It is conceivable that the rate of degradation of the peptide is substantially different in the different models used. The local injection of a large amount of peptide in the present model may overwhelm the effect of local peptide catabolism. The variability of response might also be contributed to by differing states of cell maturation in the various models used. Whitfield et al. (17) have recently shown that the C-terminal peptides of PTHrP can either stimulate or inhibit the proliferation of keratinocytes depending on the basal rate of proliferation of the cells. The present findings are in accord with those of Rouffet (18) , suggesting prevention of postovariectomy bone loss by systemic administration of PTHrP-(107-111) in rats.
In conclusion, the present report demonstrates a substantial antiosteoclastic effect of the C-terminal peptide of PTHrP in vivo and suggests that this peptide is substantially more potent than calcitonin in the same system. This work has been carried out in a totally different model from that in which the positive effects of this peptide have previously been reported and in an independent laboratory. It suggests that inhibition of osteoclast activity is a genuine effect of C-terminal PTHrP, and this might contribute to this hor- mone's critical role in fetal bone development. The inconsistency of this peptide's activity in in vitro models suggests that future studies should concentrate on systems that are as close as possible to intact human physiology.
